Enterprise Value

265.2M

Cash

24.92M

Avg Qtr Burn

N/A

Short % of Float

3.37%

Insider Ownership

4.95%

Institutional Own.

35.64%

Qtr Updated

09/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

KYNMOBI™ (apomorphine HCI) sublingual film (APL-130277) Details
Parkinson’s disease (OFF Episodes / motor fluctuations)

Approved

Quarterly sales

Exservan™ (riluzole) Oral Film Details
Amyotrophic Lateral Sclerosis (ALS)

Approved

Quarterly sales

Approved

Quarterly sales

LIBERVANT™ (Diazepam) Buccal Film Details
Seizures

Big Mover™

Susp. Mover™

PDUFA

Approval decision

Anaphylm (Epinephrine) Sublingual Film (AQST-109) Details
Anaphylaxis

Big Mover™

Susp. Mover™

Phase 3

Data readout

AQST-119 Details
Erectile dysfunction

Failed

Discontinued